Publications by authors named "A Ottlakan"

Introduction: Therapeutic treatment for advanced-stage (T-T) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.

Method: Neoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT or higher nodal positive cN+ disease (Group 2).

View Article and Find Full Text PDF

During the last decade, one of the most important treatment options for locally advanced, potencially resectable rectal tumours was neoadjuvant chemoradiotherapy (CRT) followed by surgery. Effects of the neoadjuvant treatment on surgical outcomes were retrospectively analysed in 185 patients with stage T2-T4 and N0-2, resectable rectal tumour among two patient groups defined by radiosensitizer agents. Group 1 ( = 94) involved radiotherapy (RT) with 50.

View Article and Find Full Text PDF

The aim of the current prospective pilot study exclusively for deep-seated soft tissue sarcomas (STS) was to evaluate efficacy and safety of bleomycin-based ECT using VEG (variable electrode geometry) electrodes. During a 2-year period, seven surgically inoperable STSs were treated at the University of Szeged, Department of Surgery in Hungary. Electrode placement was determined by software planning using preoperative imaging (CT/MRI) and intraoperative ultrasound.

View Article and Find Full Text PDF

Aim. Our goal was to evaluate operative and perioperative data of retroperitoneal (RP) and transperitoneal (TP) adrenalectomies performed at the University of Szeged Department of Surgery. Patients and method.

View Article and Find Full Text PDF
Article Synopsis
  • The study discusses the shift in treatment for advanced gastro-oesophageal junction cancer, using neoadjuvant chemotherapy followed by surgery, focusing on two different chemotherapy regimens: ECF/ECX (Group I) and FLOT (Group II).
  • The research involved analyzing surgical outcomes, tumor regression, and side effects from these two chemotherapy protocols in patients with T2-T4 tumors over a specific time period.
  • Results indicated that the FLOT protocol led to a significantly higher number of complete tumor regressions compared to the older ECF/ECX treatment, though no major differences in surgical safety and side effects were observed between the two groups.
View Article and Find Full Text PDF